Kuros Reshuffles Execs Post-Cytos Merger
This article was originally published in Clinica
Tissue repair and regeneration specialist Kuros Biosciences has reshuffled its senior management team following the merger with Cytos Biotechnology, completed on Jan 20. The combined company, which will take the Kuros name, is headed by Kuros Biosciences’ existing CEO Didier Cowling. Cytos’ former CEO Christian Itin is chairman of the board of directors, and vice-chair is Dominik Ellenrieder. The new Kuros’ senior executive team also includes: Alistair Irvine, chief business officer; Jason Schense, chief technology officer; and Harry Welten, chief financial officer. Zurich-based Kuros is trialing biomaterials for use in neuro- and spinal surgery. With the addition of Cytos, the combined company also has therapeutic candidates targeting the cancer and hepatitis B markets.